Exact Sciences Corp
EXAS46.000USD
+0.540+1.19%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
8.54BCap. mercado
PérdidaP/E TTM
Más Datos de Exact Sciences Corp Compañía
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Información de la empresa
Código de la empresaEXAS
Nombre de la empresaExact Sciences Corp
Fecha de salida a bolsaJan 30, 2001
Fundada en1995
Director ejecutivoMr. Kevin T. Conroy
Número de empleados6900
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección5505 Endeavor Lane
CiudadMADISON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal53719
Teléfono16082845700
Sitio Webhttps://www.exactsciences.com/
Código de la empresaEXAS
Fecha de salida a bolsaJan 30, 2001
Fundada en1995
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.43M
+1.26%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
70.57K
+9.19%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Executive Vice President
Executive Vice President
47.61K
-0.28%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
28.91K
+25.85%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
23.50K
+33.82%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.05K
+74.44%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer
Chief Financial Officer
13.62K
--
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Director
Director
6.39K
--
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Ms. Kathleen Sebelius
Ms. Kathleen Sebelius
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.43M
+1.26%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
70.57K
+9.19%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Executive Vice President
Executive Vice President
47.61K
-0.28%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
28.91K
+25.85%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
23.50K
+33.82%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.05K
+74.44%
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial
1.31B
47.44%
Medicare Parts B & C
964.10M
34.95%
Other
296.74M
10.76%
International
189.09M
6.85%
COVID 19 testing
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States (Country)
2.57B
93.15%
Outside of united states
189.09M
6.85%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial
1.31B
47.44%
Medicare Parts B & C
964.10M
34.95%
Other
296.74M
10.76%
International
189.09M
6.85%
COVID 19 testing
0.00
0.00%
Accionista
Hora de actualización: sáb., 26 de abr
Hora de actualización: sáb., 26 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
10.15%
Capital World Investors
9.44%
The Vanguard Group, Inc.
9.12%
Wellington Management Company, LLP
6.49%
BlackRock Institutional Trust Company, N.A.
4.13%
Other
60.67%
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
10.15%
Capital World Investors
9.44%
The Vanguard Group, Inc.
9.12%
Wellington Management Company, LLP
6.49%
BlackRock Institutional Trust Company, N.A.
4.13%
Other
60.67%
Tipo
Accionista
Proporción
Investment Advisor
51.55%
Investment Advisor/Hedge Fund
36.05%
Hedge Fund
6.23%
Research Firm
2.45%
Bank and Trust
1.53%
Pension Fund
1.22%
Individual Investor
1.08%
Sovereign Wealth Fund
0.50%
Private Equity
0.37%
Participación institucional
Hora de actualización: lun., 20 de ene
Hora de actualización: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1377
200.62M
108.03%
+569.91K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
2023Q1
1343
167.01M
92.90%
-8.56M
2022Q4
1337
163.71M
92.15%
-9.28M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
18.85M
10.15%
-712.35K
-3.64%
Dec 31, 2024
Capital World Investors
17.54M
9.44%
+1.70M
+10.71%
Dec 31, 2024
The Vanguard Group, Inc.
16.95M
9.12%
-741.47K
-4.19%
Dec 31, 2024
Wellington Management Company, LLP
12.06M
6.49%
-2.27M
-15.86%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.66M
4.13%
+245.10K
+3.30%
Dec 31, 2024
State Street Global Advisors (US)
6.23M
3.36%
-447.40K
-6.70%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
3.03%
+2.48M
+78.79%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.27M
2.3%
+876.99K
+25.85%
Dec 31, 2024
William Blair Investment Management, LLC
3.44M
1.85%
-840.44K
-19.61%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.12M
1.68%
+16.83K
+0.54%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
First Trust Nasdaq Lux Digi Health Solutions ETF
2.94%
First Trust NYSE Arca Biotechnology Index Fund
2.61%
Invesco Biotechnology & Genome ETF
2.34%
SPDR S&P Biotech ETF
2.09%
Nuveen ESG Mid-Cap Growth ETF
1.77%
Franklin Genomic Advancements ETF
1.42%
iShares Health Innovation Active ETF
1.39%
Direxion Daily S&P Biotech Bull 3X Shares
1.33%
ROBO Global Healthcare Technology & Innovation ETF
1.28%
VanEck Biotech ETF
1.17%
Ver más
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción2.94%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.61%
Invesco Biotechnology & Genome ETF
Proporción2.34%
SPDR S&P Biotech ETF
Proporción2.09%
Nuveen ESG Mid-Cap Growth ETF
Proporción1.77%
Franklin Genomic Advancements ETF
Proporción1.42%
iShares Health Innovation Active ETF
Proporción1.39%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.33%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.28%
VanEck Biotech ETF
Proporción1.17%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos